SynBiotic SE (XTRA: SBX)
Health Care · Pharmaceuticals · DE
€0.72
-4.67% today · -76.2% 1Y
SynBiotic SE (XTRA: SBX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.97M and employs 79 people.
Over the last twelve months the share price has lost 76.2%, trading between 0.50 and 3.85.
Tweenvest scores SynBiotic SE across four factors: value 92/100. Its strongest factor is value.
SBX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.97M
- Revenue (TTM)
- $15.38M
- P/E
- —
- EPS
- -1.66
- Dividend yield
- —
- Beta (5Y)
- 0.66
- 52-week high
- €3.85
- 52-week low
- €0.50
- Avg volume (3M)
- —
- Shares outstanding
- 6.82M
- Employees
- 79
- Next earnings
- —
About SynBiotic SE
SynBiotic SE is dedicated to pioneering cannabinoid-based pharmaceuticals and readily available health and wellness items. Its primary strategic pillars include the laboratory synthesis of cannabinoids, advanced drug discovery, the formulation of dietary aids, and the creation of cosmetic solutions. Formerly operating as Ledgertech SE, the company is headquartered in Munich, Germany.
- ISIN
- DE000A3E5A59
- Founded
- 2024
- Listed since
- Jan 7, 2021
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.